Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The RA-BE-REAL Multinational, Prospective, Observational Study in Patients with Rheumatoid Arthritis Receiving Baricitinib, Targeted Synthetic, or Biologic Disease-Modifying Therapies: a 6-Month Interim Analysis.
Alten R, Burmester GR, Matucci-Cerinic M, Salmon JH, Lopez-Romero P, Fakhouri W, de la Torre I, Zaremba-Pechmann L, Holzkämper T, Fautrel B. Alten R, et al. Among authors: holzkamper t. Rheumatol Ther. 2023 Feb;10(1):73-93. doi: 10.1007/s40744-022-00500-6. Epub 2022 Oct 13. Rheumatol Ther. 2023. PMID: 36227530 Free PMC article.
Assessment of the association of baseline anti-CarbV and anti-MCV antibodies with response to treatment and radiographic progression in an RA population treated with either methotrexate or baricitinib: post-hoc analyses from RA-BEGIN.
López-Romero P, Martinez-Gamboa L, Bang H, de la Torre I, Holzkämper T, Feist E. López-Romero P, et al. Among authors: holzkamper t. Arthritis Res Ther. 2020 Aug 18;22(1):193. doi: 10.1186/s13075-020-02284-y. Arthritis Res Ther. 2020. PMID: 32811536 Free PMC article.
Comparative Effectiveness of Biologics Across Subgroups of Patients with Moderate-to-Severe Plaque Psoriasis: Results at Week 12 from the PSoHO Study in a Real-World Setting.
Lynde C, Riedl E, Maul JT, Torres T, Pinter A, Fabbrocini G, Daniele F, Brnabic A, Reed C, Wilhelm S, Holzkämper T, Schuster C, Puig L. Lynde C, et al. Among authors: holzkamper t. Adv Ther. 2023 Mar;40(3):869-886. doi: 10.1007/s12325-022-02379-9. Epub 2022 Dec 14. Adv Ther. 2023. PMID: 36515803 Free PMC article.
A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis.
Kirkham BW, Egeberg A, Behrens F, Pinter A, Merola JF, Holzkämper T, Gallo G, Ng KJ, Bolce R, Schuster C, Nash P, Puig L. Kirkham BW, et al. Among authors: holzkamper t. Rheumatol Ther. 2023 Oct;10(5):1127-1146. doi: 10.1007/s40744-023-00553-1. Epub 2023 Jul 3. Rheumatol Ther. 2023. PMID: 37400681 Free PMC article. Review.